Targeting the "rigid demand" of future pharmaceutical companies, the pharmaceutical equipment industry needs "1 to make up 1 increase"

Pharmaceutical Network Market AnalysisBiopharmaceuticals, an important part of the national economy, has now risen to become a national strategic emerging industryIn recent years, with the rapid development of the biopharmaceutical industry, accelerating the research and development of biopharmaceutical equipment has become an important issueaiming at the "rigid demand" of future pharmaceutical companies, pharmaceutical equipment industry needs "1 to make up 1 increase" (source: pharmaceutical network)the size of the biopharmaceutical market is huge
2025 or exceed 500 billion yuan
data show that in 2018 China's biopharmaceutical industry market size has exceeded 350 billion yuan, a total of 9 independent research and development of a new class of 1 new drugs approved for marketAccording to the 2020 China Biopharmaceutical Industry Park Development Prospects and Investment Research Report released by the China Institute of Industry and Industry, data show that by 2020, China's biopharmaceutical industry market size will be nearly 400 billion yuanin addition, with the aging of the population, people's consumption is escalating, as well as in the strategic emerging industries, science and technology board to open a "green channel" to encourage innovative drugs and other favorable policies, supported by the biopharmaceutical industry market prospects are considerableindustry expects that the domestic biopharmaceutical industry market will maintain a growth rate of 10%-15% between 2020 and 2025, and the market size will exceed the 500 billion yuan mark by 2025"Biopharmaceuticals and even innovative pharmaceutical companies will be the focus of capital for a long time to come"There are people in the industry who say soAiming at the "rigid demand" of the future pharmaceutical companies
pharmaceutical equipment industry needs "1 to add" biomedicine and high-performance medical devices are listed as "Made in China 2025" one of the ten key areas, the core and intrinsic driving force of its future development lies in innovation Industry pointed out that in the future, pharmaceutical equipment high-end, "pharmaceutical industry 4.0" and intelligent manufacturing will be regarded as the "rigid demand" of pharmaceutical companies Combined with the current development of the pharmaceutical equipment industry, the author believes that the pharmaceutical equipment industry needs "1 supplement 1 increase." - "1 complement" to make up the short board At present, the domestic low-end pharmaceutical equipment has basically achieved import substitution, but in the middle and high-end areas, domestic pharmaceutical equipment still has short board difficult to enter Many pharmaceutical companies come into contact with equipment, especially high-precision instruments, which are basically imported products Take centrifuges as an example, for technical reasons, imported frozen centrifuges have long occupied most of the domestic market, distributed throughout the country's laboratories, as well as universities and related enterprises With the rapid development of the domestic biopharmaceutical industry, accelerating the development of high-end biopharmaceutical equipment will become an important issue The industry believes that strengthening investment in research and development is the key Domestic pharmaceutical machine enterprises need to continue to carry out technological innovation, enhance the added value of products, towards the middle and high-end areas continue to move forward - "1 increase" to increase the momentum In recent years, with the rapid development of automation, intelligence, information technology, the pharmaceutical equipment industry has been towards the "pharmaceutical industry 4.0" and medical intelligent manufacturing upgrade direction The industry expects to feel a significant change in five years, and a pattern change in 10 years In the industry's view, "Pharmaceutical Industry 4.0" can guarantee the quality and safety of medicines, greatly reduce the rising human costs, to help the pharmaceutical industry high-quality, green and sustainable development according to the introduction, pharmaceutical intelligent manufacturing and "pharmaceutical industry 4.0" can achieve immediate, online, full-scale production and circulation of drugs to automatically monitor consumption, and automatically generate data (and not tamperable), automatically read data, automatic data storage to the cloud, zero delay, no dead end, no blind spot Under legal authorization, regulators, drug producers and consumers can access and access the data the author learned that a number of pharmaceutical machine enterprises have been in this regard For example, pharmaceutical machine enterprises have used automation and information technology, developed some intelligent pharmaceutical production robots and related production lines, is to build a "pharmaceutical industry 4.0" smart factory overall solution of the EPC service provider transformation; but overall, at present, the domestic biotechnology level, biopharmaceutical core equipment such as tomography ultrafiltration equipment, online dispensing system, bioreactor, etc., compared with the international high level, there is still a big gap In this regard, the industry suggested that domestic pharmaceutical enterprises in the efforts to innovate research and development, increase the strength of the same, but also need more policies and supporting policies to support, in the enterprise capital, talent, technology and other aspects of sustained efforts.